NCT06790160 Study of Patients Being Treated With Anti-obesity Medication
| NCT ID | NCT06790160 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Texas Tech University |
| Condition | Obesity and Overweight |
| Study Type | OBSERVATIONAL |
| Enrollment | 100 participants |
| Start Date | 2025-01-31 |
| Primary Completion | 2027-02 |
Trial Parameters
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
Brief Summary
The goal of this observational study is to learn about the real-world effects of selected obesity medications in adults undergoing medical weight management. The main outcomes of interest are changes in body composition, routine clinical markers, muscular performance, and nutritional intake over the course of treatment. Additionally, the influence of lifestyle factors on changes in these outcome variables will be examined. Participants beginning treatment with selected obesity medications will undergo periodic body composition and muscular performance testing, as well as complete online surveys about their nutritional intake and physical activity and exercise participation. Additionally, routinely collected clinical information will be evaluated.
Eligibility Criteria
Inclusion Criteria: * Patient who is beginning treatment through Vineyard Virtual Health Clinic using semaglutide or tirzepatide. While the physician will individualize the treatment plans, the criteria for these medications will include, at a minimum: (A) a body mass index ≥30 kg/m2; OR (B) a BMI ≥27 kg/m2 plus at least one comorbidity. * Patient who lives in drivable proximity to a city with an accepted DXA testing facility and is willing to report to the facility for periodic body composition testing. Exclusion Criteria: * Patients with type 2 diabetes. * Patients who report not being willing or able to complete the assessments included in this research study. * Patients who are currently pregnant or trying to become pregnant.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.